Virtus ETF Advisers LLC Atara Biotherapeutics, Inc. Transaction History

Virtus ETF Advisers LLC

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$2.8 - $5.46 $28,072 - $54,741	-10,026 Reduced 27.77%	26,074 $75,000
Q4 2022 Feb 14, 2023	BUY	$2.85 - $5.18 $45,189 - $82,134	15,856 Added 78.32%	36,100 $118,000
Q3 2022 Nov 14, 2022	BUY	$2.85 - $8.73 $418 - $1,283	147 Added 0.73%	20,244 $77,000
Q2 2022 Aug 12, 2022	BUY	$4.69 - $9.84 $47,978 - $100,663	10,230 Added 103.68%	20,097 $157,000
Q1 2022 May 16, 2022	SELL	$8.44 - $16.89 $4,971 - $9,948	-589 Reduced 5.63%	9,867 $92,000
Q4 2021 Feb 14, 2022	SELL	$14.7 - $19.89 $59,402 - $80,375	-4,041 Reduced 27.87%	10,456 $165,000
Q3 2021 Nov 15, 2021	SELL	$11.99 - $17.9 $9,124 - $13,621	-761 Reduced 4.99%	14,497 $259,000
Q2 2021 Aug 10, 2021	BUY	$12.89 - $16.58 $31,915 - $41,052	2,476 Added 19.37%	15,258 $237,000
Q1 2021 May 17, 2021	BUY	$14.0 - $20.72 $3,052 - $4,516	218 Added 1.74%	12,782 $184,000
Q4 2020 Feb 12, 2021	SELL	$12.67 - $26.23 $257,175 - $532,416	-20,298 Reduced 61.77%	12,564 $247,000
Q3 2020 Nov 13, 2020	SELL	$11.92 - $15.87 $53,389 - $71,081	-4,479 Reduced 11.99%	32,862 $426,000
Q2 2020 Aug 05, 2020	BUY	$7.53 - $14.93 $105,947 - $210,065	14,070 Added 60.46%	37,341 $544,000
Q1 2020 May 14, 2020	SELL	$5.69 - $17.78 $19,317 - $60,363	-3,395 Reduced 12.73%	23,271 $198,000
Q4 2019 Feb 13, 2020	BUY	$10.89 - $16.79 $164,515 - $253,646	15,107 Added 130.69%	26,666 $439,000
Q3 2019 Nov 12, 2019	SELL	$12.03 - $19.94 $7,747 - $12,841	-644 Reduced 5.28%	11,559 $163,000
Q2 2019 Aug 13, 2019	BUY	$19.05 - $41.04 $232,467 - $500,811	12,203 New	12,203 $245,000

2.89M

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $1.08B
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Virtus ETF Advisers LLC with notifications on news.